论文部分内容阅读
本实验发现ADPRT抑制剂3 AB2.5mmol/kg与BLM2.5mg/kg联合用药,便BLM对S180的抑瘤率从42.5％、46.1％提高到66.2％、75.9％,而小鼠体霞无明显减轻。BLM 5mg/kg单独用药,抑瘤率为64.8％、75％、抗瘤作用与上述联合用药组相当-但其体重减轻更为明显。3AB在有协同抗瘤作用的剂量下,对BLM的急性毒性无增毒作用。在亚急性毒性方面,通过观察小鼠体重变化、外周血白细胞计数、肺形态学表现及肺湿重、羟脯氨酸含量,发现3 AB对BLM的毒性无增强作用。实验为更有效地将无明显毒性的ADPRT抑制剂与BLM联合用药治疗肿瘤提供了实验依据。
In this experiment, ADPRT inhibitor 3 AB2.5mmol/kg was combined with BLM2.5mg/kg, the inhibition rate of BLM on S180 increased from 42.5%, 46.1% to 66.2%, 75.9%, and the body growth of mice was not obvious. Reduce. BLM 5mg/kg alone medication, tumor inhibition rate of 64.8%, 75%, anti-tumor effect and the combination of the above-mentioned drug group was equivalent - but its weight loss is more obvious. At doses with synergistic anti-tumor effect, 3AB had no toxic effect on the acute toxicity of BLM. In terms of sub-acute toxicity, the effects of 3 AB on BLM toxicity were observed by observing changes in body weight, peripheral white blood cell count, lung morphology, lung wet weight, and hydroxyproline content. The experiment provides experimental basis for more effective treatment of tumors with ADPRT inhibitors with no obvious toxicity combined with BLM.